Skip to content

Microbiome-Targeted Enhancement of Neurocognition With Probiotics-Riboflavin Combination

Microbiome-Targeted Enhancement of Neurocognition With Probiotics-Riboflavin Combination (MENTOR)

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07410052
Acronym
MENTOR
Enrollment
28
Registered
2026-02-13
Start date
2026-04-15
Completion date
2027-08-15
Last updated
2026-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Deficits, Mild

Keywords

Bioenergetics, Sleep quality, Cognition, Oxygenation

Brief summary

This randomized, double-blind, placebo-controlled trial will evaluate whether 12 weeks of supplementation with the probiotic Lactobacillus rhamnosus GG combined with colon-delivered riboflavin will improve cognitive performance and brain physiology in older adults with memory complaints. The study will assess changes in cognitive outcomes together with neurophysiological markers to explore potential gut-brain axis mechanisms. Through its rigorous design, the trial will aim to determine whether targeted modulation of the intestinal environment can support brain function and cognitive health in aging.

Interventions

DIETARY_SUPPLEMENTExperimental 1

Probiotic and riboflabin

DIETARY_SUPPLEMENTExperimental 2

Microcrystaline cellulose

Sponsors

Center for Health Sciences, Serbia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age \> 65 years * MoCA scores 18-25 points * BMI of 20.0 - 29.9 kg/m2 at screening * Stable body weight (≤ 5% change) over the past 3-months * Willing to avoid consuming gut microbiome-modulating dietary supplements within 4 weeks prior to the baseline visit * Subjects will abstain from vitamin B2-rich food intake as per pre-defined list * Maintain current level of physical activity * Be willing and able to comply with trial protocol

Exclusion criteria

* Severe chronic disease and acute injuries * History of dietary supplement use four weeks before enrolment * Organic gastrointestinal (GI) disorders * Bowel surgery or short bowel syndrome * Gut-altering medications two months before enrolment * Is currently using systemic steroids, proton pump inhibitors, H2 blocker, antacid * History of drug and/or alcohol abuse at the time of enrolment * Smoker or vaper * Has made any major dietary changes in the past 3 months prior to baseline * Has a currently active eating disorder * Has food allergies or other issues with foods

Design outcomes

Primary

MeasureTime frameDescription
Montreal Cognitive Assesment scoresChange from baseline The Montreal Cognitive Assessment (MoCA) score at 12 weeksThe Montreal Cognitive Assessment (MoCA) score is a brief, 30-point screening measure of global cognitive function. It assesses multiple domains, including memory, attention, executive function, language, visuospatial abilities, and orientation. Higher scores indicate better cognitive performance, with a score of 26 or above generally considered within the normal range, while lower scores suggest varying degrees of cognitive impairment.

Secondary

MeasureTime frameDescription
Mini-Mental State Examination ScoreChange from baseline Mini-Mental State Examination Score at 12 weeksThe Mini-Mental State Examination score quantifies global cognitive function by assessing orientation, memory, attention, language, and visuospatial abilities, offering a validated measure for detecting cognitive decline in older adults.
Pittsburgh Sleep Quality Index (PSQI)Change from baseline PSQI at 12 weeksThe Pittsburgh Sleep Quality Index (PSQI) is a self-report tool used to assess sleep quality and disturbances. It consists of 19 items covering seven components: sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, daytime dysfunction, and use of sleep medications. Each component is scored from 0 to 3, with higher scores indicating worse sleep quality. The total score ranges from 0 to 21, where a score of 5 or higher suggests poor sleep quality. The PSQI is widely used in clinical and research settings to evaluate sleep health.
Brain oxygen saturationChange from baseline hemoglobin index at 12 weeksConcentration of hemoglobin index in prefrontal brain
Grip strengthChange from baseline grip strength at 12 weeksMuscular strength generated by one's forearm muscles

Contacts

CONTACTSergej Ostojic, MD, PhD
sergej.ostojic@chess.edu.rs+381112643242
PRINCIPAL_INVESTIGATORNikola Todorovic, PhD

Center for Mitochondrial Medicine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026